Cardiometabolic multimorbidity (CMM), defined as the presence of two or more cardiometabolic conditions such as type 2 diabetes, stroke, and coronary heart disease, is an expanding global health problem. Prior studies have examined metabolic dysfunction and biological aging as separate contributors to cardiometabolic risk, but their combined effect across the disease continuum and potential for improving risk stratification has been less well characterized. This study evaluated whether joint assessment of metabolic dysfunction and biological age improves prediction of CMM incidence and disease progression.
This prospective cohort study used data from the China Health and Retirement Longitudinal Study (CHARLS). The analytic sample comprised 8,767 participants aged 45 years and older who did not have CMM at baseline. Baseline biomarkers included the triglyceride–glucose (TyG) index and two biological age algorithms: Light BA and KDM BA. Biological age acceleration (BAA) was derived as the residual from regressing biological age on chronological age.
The primary outcome was incident CMM over follow-up. Median follow-up time was 108 months. During follow-up, 873 participants were newly diagnosed with CMM. The study also examined transitions across the cardiometabolic disease continuum and mortality using multistate models.
Continuous TyG–BA composite indices were constructed as the product of TyG and biological age measures. Repeated measurements from 2011 and 2015 were used to assess cumulative exposure and two-wave trajectories. Cox proportional hazards models estimated associations and dose–response relationships, including restricted cubic spline analyses for nonlinearity. Time-dependent discrimination analyses assessed incremental predictive performance, and multistate models evaluated associations across disease transitions.
Both TyG and biological age measures were independently associated with incident CMM. In mutually adjusted models, hazard ratios per standard-deviation (SD) increase were approximately 1.23–1.27 for TyG and 1.39–1.44 for biological age. Individuals with both elevated TyG and accelerated biological aging experienced the greatest risk: hazard ratios were 2.37 when using Light BA and 2.26 when using KDM BA, compared with the reference group. The authors report no significant multiplicative interaction between TyG and biological age.
Continuous TyG–BA composites showed strong associations: a per-SD increase in the composite was associated with a 49% to 62% higher risk of CMM. Comparing the highest versus lowest quartile of the composite yielded more than a threefold higher CMM risk. Dose–response relationships were nonlinear according to spline analyses.
Higher cumulative exposure to elevated TyG–BA composite values and persistently elevated two-wave trajectories were associated with substantially increased CMM risk. Hazard ratios comparing highest versus lowest exposure groups ranged from 3.93 to 5.17. Multistate analyses indicated that the TyG–BA composites were consistently associated with transitions across stages of cardiometabolic disease and with mortality, indicating relevance across the disease continuum.
When TyG–BA composites were added to a prespecified clinical prediction model, the concordance index (C-index) increased by 0.015 to 0.024, and net clinical benefit improved. However, the composites did not improve discrimination beyond models that retained TyG and biological age as separate covariates. Thus, the composite provides a parsimonious summary of combined burden but is not necessarily superior to using the two components separately for prediction.
Exploratory subgroup analyses suggested stronger associations in younger participants and those without frailty. These subgroup findings were described as exploratory and warrant further validation.
The study concludes that metabolic dysfunction and biological aging represent complementary, partly independent dimensions of susceptibility to CMM and its progression. TyG–BA composites summarize the joint metabolic–aging burden and modestly improve risk discrimination beyond conventional clinical factors, supporting the concept of a metabolic aging framework for risk stratification. The authors recommend external validation, particularly to assess utility in earlier stages of cardiometabolic disease development.
Ethical approval for CHARLS was granted by Peking University's Biomedical Ethics Review Committee (IRB00001052-11015), and participants gave written informed consent. The authors declared no competing interests. Specific limitations beyond the need for external validation were not detailed in the source article text provided.